DiagnoCure Begins Trading on OTCQX®

                     DiagnoCure Begins Trading on OTCQX®

PR Newswire

NEW YORK, April 2, 2013

NEW YORK, April 2, 2013 /PRNewswire/ --OTC Markets Group Inc. (OTCQX: OTCM),
operator of Open, Transparent and Connected financial marketplaces, today
announced that DiagnoCure Inc. (OTCQX: DGCRF; TSX: CUR), a life sciences
company that develops and commercializes high-value cancer diagnostic tests,
has chosen to trade on OTCQX®, the best OTC marketplace with qualified

(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO )

DiagnoCure will begin trading today on OTCQX International, a segment of the
OTCQX marketplace reserved for high-quality non-U.S. companies listed on a
qualified stock exchange in their home country. Investors can find current
financial disclosure and Real-Time Level 2 quotes for the company on

"We are pleased DiagnoCure has chosen to trade on OTCQX," said R. Cromwell
Coulson, President and CEO of OTC Markets Group. "OTCQX is the highest OTC
marketplace offering qualifying companies the means to grow their U.S.
shareholder base through high-quality disclosure, transparent trading and ease
of access to company information."

"We are proud to join OTCQX, which will enable us to provide our U.S.
investors with timely news and information to help them better analyze, value
and trade our securities," said Chantal Miklosi, Chief Financial Officer of

Dorsey & Whitney LLP will serve as DiagnoCure's Principal American Liaison
("PAL") on OTCQX, responsible for providing professional guidance on OTCQX
requirements and U.S. securities laws.

DiagnoCure is a life sciences corporation that develops and commercializes
high-value cancer diagnostic tests that increase clinician and patient
confidence in making critical treatment decisions. In 2008, the corporation
launched a colorectal cancer staging test through its U.S. CLIA laboratory.
Previstage™GCC is currently available for licensing. The company has
granted a worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development
and commercialization of prostate cancer test using PCA3, DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is
commercialized in Europe under CE mark and is approved for commercialization
in Canada and the United States.

DiagnoCure trades in the U.S. on OTCQX under the symbol "DGCRF."

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected
financial marketplaces for 10,000 U.S. and global securities. Through our OTC
Link® ATS, we directly link a diverse network of broker-dealers that provide
liquidity and execution services for a wide spectrum of securities. We
organize these securities into marketplaces to better inform investors of
opportunities and risks – OTCQX®, The Best Marketplace with Qualified
Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting
Companies; and OTC Pink®, The Open Marketplace with Variable Reporting
Companies. Our data-driven platform enables investors to easily trade through
the broker of their choice at the best possible price and empowers a broad
range of companies to improve the quality and availability of information for
their investors. To learn more about how we create better informed and more
efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated

Subscribe to the OTCQX RSS Feed

SOURCE OTC Markets Group Inc.

Website: http://www.otcmarkets.com
Contact: Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428,
Press spacebar to pause and continue. Press esc to stop.